Seelos Therapeutics Inc (NASDAQ:SEEL) Short Interest Up 7.1% in July

Seelos Therapeutics Inc (NASDAQ:SEEL) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 831,900 shares, an increase of 7.1% from the June 30th total of 776,600 shares. Based on an average daily volume of 436,600 shares, the days-to-cover ratio is currently 1.9 days. Currently, 28.7% of the shares of the stock are short sold.

SEEL opened at $1.58 on Friday. Seelos Therapeutics has a 1-year low of $1.32 and a 1-year high of $12.90. The stock has a 50 day moving average price of $1.85.

Seelos Therapeutics (NASDAQ:SEEL) last issued its earnings results on Thursday, August 1st. The company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.06. On average, sell-side analysts anticipate that Seelos Therapeutics will post -4.3 EPS for the current year.

A number of research firms have weighed in on SEEL. ValuEngine upgraded shares of Seelos Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Seelos Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research report on Tuesday, August 6th. HC Wainwright began coverage on shares of Seelos Therapeutics in a research report on Friday, May 10th. They issued a “buy” rating and a $4.00 price target for the company. Finally, Roth Capital set a $8.00 price target on shares of Seelos Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 2nd.

Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its position in shares of Seelos Therapeutics by 95.0% during the second quarter. Renaissance Technologies LLC now owns 929,465 shares of the company’s stock worth $2,036,000 after acquiring an additional 452,700 shares during the last quarter. BlackRock Inc. boosted its position in shares of Seelos Therapeutics by 15.3% during the second quarter. BlackRock Inc. now owns 311,528 shares of the company’s stock worth $682,000 after acquiring an additional 41,256 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Seelos Therapeutics by 104.2% during the second quarter. Vanguard Group Inc. now owns 239,222 shares of the company’s stock worth $524,000 after acquiring an additional 122,086 shares during the last quarter. A.R.T. Advisors LLC boosted its position in shares of Seelos Therapeutics by 371.5% during the second quarter. A.R.T. Advisors LLC now owns 52,342 shares of the company’s stock worth $115,000 after acquiring an additional 41,242 shares during the last quarter. Finally, Ardsley Advisory Partners LP boosted its position in shares of Seelos Therapeutics by 25.0% during the second quarter. Ardsley Advisory Partners LP now owns 50,000 shares of the company’s stock worth $110,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 4.92% of the company’s stock.

About Seelos Therapeutics

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.

Featured Story: Holder of Record

Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.